.jpg?format=webp&width=780)
This study aimed to investigate factors associated with proteinuria regression in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin. This study compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N‐terminal pro‐brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF). In patients with T2DM and CHF, regression of proteinuria with canagliflozin treatment was associated with the pretreatment insulin level. These results may provide clinicians with novel mechanistic insights into the beneficial effects of canagliflozin on renal outcomes. In addition, they may warrant discussion for selecting preferred patient profiles, including pretreatment insulin levels.
Like
Save
Share